 BARCELONA, Spain, Nov. 7, 2019 PRNewswire -- Grifols MCE: GRF, MCE: GRF.P NASDAQ: GRFS, a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, has now introduced AlphaIDTM, a new, simple cheek swab that can be used by physicians to screen patients with chronic obstructive pulmonary disease COPD for alpha-1 antitrypsin deficiency Alpha-1, a rare, life-threatening genetic condition. 